Abstract Library

#4616 Clinical characterisation of patients with familial midgut neuroendocrine tumours (FM-NETs) based on a comparison with the large population-based GTE/RENATEN cohort

Introduction: The clinical specificities of FM-NET have been poorly described.

Conference:

Presenting Author: Hunaut T

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: Small intestine neuroendocrine tumour, Familial carcinoid tumour,

#4562 Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,

#4378 Hypoxic signalling in pancreatic NETs (pNETs)

Introduction: In a genomic profiling study conducted as part of the COMPOSE Phase III multicentre open-labelled clinical trial we assessed 9 pNET patients, 2 of which showed upregulation of CA9 and hypoxic signalling. Hypoxic tumour cells present CA9 for extracellular proton channelling, maintenance of intracellular pH and to acidify and thereby vascularise and immune-suppress the TME. In normoxia, EGLN1-3 hydroxylate proline residues of HIF1A for its subsequent ubiquitination by the VHL-complex resulting in degradation and repression of its target genes.

Conference:

Presenting Author: Walter T

Authors: Walter T, Smutna V, Srirajaskanthan R, Capdevila J, Qin Y,

Keywords: hypoxia, pNET, HIF1A, CA9, Case study, hypoxic, genomic profiling,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,